Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1Myelodysplastic Syndromes 1Leukemia 1Inflammatory Breast Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Interventional × NOV 002 × Clear all
NCT00499122 2018-01-02

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

University of Miami

Phase 2 Completed
41 enrolled 10 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00345540 2015-03-10

Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer

Cellectar Biosciences, Inc.

Phase 2 Completed
15 enrolled 8 charts
Gynecologic

Ovarian Neoplasms

NCT00960726 2012-07-30

NOV-002 in Myelodysplastic Syndrome (MDS)

M.D. Anderson Cancer Center

Phase 2 Withdrawn
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡